Stockreport

Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial [Yahoo! Finance]

Immunic, Inc.  (IMUX) 
PDF The trial evaluated vidofludimus calcium (IMU-838), which is an orally available nuclear receptor-related 1 (Nurr1) activator, in patients with relapsing-remitting multi [Read more]